CorMedix Inc.
CRMD · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 162.4% | 1.7% | 25.2% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 89.3% | 95.3% | 95.9% | 96.2% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | $0 | $0 | $0 | $0 |
| % Margin | 49.2% | 49.2% | 51.5% | 41.4% |
| Other Income/Exp. Net | $0 | $0 | $0 | $0 |
| Pre-Tax Income | $0 | $0 | $0 | $0 |
| Tax Expense | -$0 | $0 | $0 | $0 |
| Net Income | $0 | $0 | $0 | $0 |
| % Margin | 104.1% | 49.9% | 52.8% | 43.1% |
| EPS | 1.42 | 0.29 | 0.32 | 0.22 |
| % Growth | 389.7% | -9.4% | 45.5% | – |
| EPS Diluted | 1.26 | 0.28 | 0.3 | 0.22 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 55% | 51.6% | 53.3% | 43.6% |